<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02790190</url>
  </required_header>
  <id_info>
    <org_study_id>CRTOG1601</org_study_id>
    <nct_id>NCT02790190</nct_id>
  </id_info>
  <brief_title>Individualized Adaptive Radiotherapy Based on PET/CT and IMRT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Phase III Study of Individualized Adaptive Radiotherapy Based on PET/CT and 3DCRT/IMRT in Combination With Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Cancer Hospital and Institute</source>
  <brief_summary>
    <textblock>
      This is a perspective, multicenter,randomized controlled trial to compare the efficacy and
      safety of radiotherapy Based on PET/CT and IMRT combined with concurrent chemotherapy in
      patients with locally advanced non small cell lung cancer . Analyses of overall survival (OS)
      will be done as defined in the protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      https://register.clinicaltrials.gov/prs/app/template/Home.vm?uid=U000184Z&amp;ts=76&amp;sid=S0006AP2&amp;
      cx=r0ratc
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local control rate</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>Individualized Adaptive radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GTV dose per fraction will be 2.2-2.4 y per fraction for 20 fractions and PTV dose per fraction will be 2.0 Gy per fraction.Perform PET/CT before radiotherapy and at 36 Gy for treatment response assessment and adaptive plan.Adaptive plan treated at 2.2-3.8 Gy per fraction for GTV and 2.0 Gy for PTV in the final 10 fractions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional radiotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>2 Gy per fraction for all patient,perform PET/CT before radiotherapy and at 40 Gy for treatment response assessment .Continue treatment to a total dose of 60 Gy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radiotherapy dose</intervention_name>
    <arm_group_label>Individualized Adaptive radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically proven non-small cell lung cancer.

          2. Patients must be clinical AJCC stage IIIA or IIIB (AJCC, 7th ed.) with non-operable
             disease; non-operable disease will be determined by a multidisciplinary treatment
             team.

          3. Patients with multiple, ipsilateral pulmonary nodules (T3, or T4) are eligible if a
             definitive course of daily fractionated RT is planned.

          4. Appropriate stage for protocol entry, including no distant metastases, based upon the
             following minimum diagnostic workup:

               1. History/physical examination, including documentation of weight, within 2 weeks
                  prior to registration;

               2. CT scan or sim CT of chest and upper abdomen (IV contrast is recommended unless
                  medically contraindicated) within 6 weeks prior to registration;

               3. CT scan of the brain (contrast is recommended unless medically contraindicated)
                  or MRI of the brain within 6 weeks prior to registration;

               4. Pulmonary function tests, including DLCO, within 6 weeks prior to registration;
                  patients must have FEV1 ≥ 1.2 Liter or ≥ 50% predicted without bronchodilator;

               5. Zubrod Performance Status 0-1 within 2 weeks prior to registration;

               6. Age ≥ 18;

               7. Able to tolerate PET/CT imaging required to be performed at an ACR Imaging Core
                  Lab qualified facility;

               8. CBC/differential obtained within 2 weeks prior to registration on study, with
                  adequate bone marrow function;

          5. Serum creatinine within normal institutional limits or a creatinine clearance ≥ 60
             ml/min within 2 weeks prior to registration;

          6. The patient must provide study-specific informed consent prior to study entry.

        Exclusion Criteria

          1. Any component of small cell lung carcinoma.

          2. Evidence of a malignant pleural or pericardial effusion .

          3. Prior invasive malignancy (except nonmelanomatous skin cancer) in 3 years ;

          4. Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a
             different cancer is allowable.

          5. Prior radiotherapy to the region of the study cancer that would result in overlap of
             radiation therapy fields;

          6. Severe, active co-morbidity, defined as follows:

             Unstable angina and/or congestive heart failure requiring hospitalization within the
             last 6 months; Transmural myocardial infarction within the last 6 months; Acute
             bacterial or fungal infection requiring intravenous antibiotics at the time of
             registration; Hepatic insufficiency resulting in clinical jaundice and/or coagulation
             defects; note, however, that laboratory tests for liver function and coagulation
             parameters are not required for entry into this protocol; Acquired Immune Deficiency
             Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is
             not required for entry into this protocol. The need to exclude patients with AIDS from
             this protocol is necessary because the treatments involved in this protocol may be
             significantly immunosuppressive. Protocol-specific requirements may also exclude
             immuno-compromised patients.

          7. Pregnancy or women of childbearing potential and men who are sexually active and not
             willing to use medically acceptable forms of contraception.

          8. Poorly controlled diabetes (defined as fasting glucose level &gt; 200 mg/dL) ;

          9. Patients with T4 disease with radiographic evidence of massive invasion of a large
             pulmonary artery and tumor causing significant narrowing and destruction of that
             artery are excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuanghu Yuan, Ph.D ， M.D</last_name>
    <role>Study Director</role>
    <affiliation>Shandong Cancer Hospital and Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinming Yu, Ph.D ， M.D</last_name>
    <phone>13806406293</phone>
    <email>sdyujinming@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shuanghu Yuan, Ph.D ， M.D</last_name>
    <phone>13853106916</phone>
    <email>yuanshuanghu@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lvhua Wang</last_name>
      <phone>13601283715</phone>
      <email>wlhwq@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Lvhua Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Province Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiancheng Li, PhD</last_name>
      <phone>8613906900190</phone>
      <email>jianchengli6@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>qin lin</last_name>
      <email>linqin05@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liuzhou worker's hospital</name>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dongning Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fourth hospital of hebei medical university</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>jun wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>the second Hospital of hebei medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>xiaoying xue</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated tumour Hospital of haerbin Medical University</name>
      <address>
        <city>Haerbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiangying xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Cancer Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hong Ge</last_name>
      <email>gehong666@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gang Wu, PhD</last_name>
      <phone>8613871240042</phone>
      <email>wugangzr@yahoo.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hubei Provincial Renmin Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>qibin song</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guang Li</last_name>
      <phone>13804058616</phone>
      <email>13804058616@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jun Dang</last_name>
      <phone>13898150850</phone>
      <email>dangjunsy@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Guang Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Dang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qianfoshan Hospital of Shandong</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiandong Zhang</last_name>
      <phone>13583123486</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital and Institute</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuanghu Shuanghu</last_name>
      <phone>13853106916</phone>
      <email>yuanshuanghu@sina.com</email>
    </contact>
    <investigator>
      <last_name>Shuanghu Shuanghu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The affiliated hospital of qingdao university</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>haijun lu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teng Zhou Central People's Hospital</name>
      <address>
        <city>Tengzhou</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kaixian Zhang</last_name>
      <email>kaixianzhang@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yipeng song</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>xiaolong Fu</last_name>
      <email>13651635103@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xijing hopital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mei Shi</last_name>
      <email>214696138@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the Affiliated Hospital of southwest medicalUniversity</name>
      <address>
        <city>Luzhou</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>jingbo wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Tumor Hospital of Xinjiang Medical University</name>
      <address>
        <city>Wulumuqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruozheng Wang</last_name>
      <email>wrz8526@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Hangzhou</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shenglin Ma, PhD</last_name>
      <phone>8613588799118</phone>
      <email>mashenglin@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Medical School of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Senxiang Yan</last_name>
      <email>yansenxiang@zju.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>YAPING XU</last_name>
      <email>xuyaping1207@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital of wenzhou medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>congying xie</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2016</study_first_submitted>
  <study_first_submitted_qc>May 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2016</study_first_posted>
  <last_update_submitted>May 29, 2016</last_update_submitted>
  <last_update_submitted_qc>May 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Cancer Hospital and Institute</investigator_affiliation>
    <investigator_full_name>Jinming Yu</investigator_full_name>
    <investigator_title>president</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

